The combination of anti-estrogen fulvestrant and an EGFR-TKI such as gefitinib or erlotinib can maximally inhibit lung cancer cell proliferation, induce apoptosis and reduce downstream signaling pathways both in vivo and in vitro (27, 29). The gene discussed is EGFR; the disease is lung carcinoma.